Related Experiment Videos
Breast implants and cancer risk in Denmark
S Friis1, J K McLaughlin, L Mellemkjaer
1Danish Cancer Society, Division of Cancer Epidemiology, Copenhagen.
International Journal of Cancer
|June 11, 1997
Summary
This study found no increased cancer risk in women with breast implants up to 17 years post-surgery. Further long-term research is needed to fully assess potential adverse effects of breast implants.
Area of Science:
- Oncology
- Plastic Surgery
- Epidemiology
Background:
- Millions of women use breast implants for cosmetic and medical reasons globally.
- Potential long-term health effects, particularly cancer, remain understudied.
- Assessing cancer risk associated with breast implants is crucial for patient safety.
Purpose of the Study:
- To quantitatively evaluate cancer occurrence in women who received breast implants for cosmetic reasons.
- To determine if breast implants are associated with an increased risk of cancer.
- To provide data for informed decision-making regarding breast implant procedures.
Main Methods:
- A cohort of 1,135 women undergoing cosmetic breast implant surgery in Denmark was identified.
- Data linkage between the nationwide Hospital Discharge Registry and the Danish Cancer Registry was used.
- Cancer incidence was compared to expected rates in the general population over an average follow-up of 8.4 years.
Main Results:
- A total of 27 cancers were diagnosed post-surgery, closely matching the expected 24.7 cases (Standardized Incidence Ratio [SIR] = 1.1).
- Eight breast cancers were observed, aligning with the expected 7.8 cases (SIR = 1.0).
- No statistically significant increase in overall or breast cancer risk was detected within the first decade after surgery.
Conclusions:
- The study found no evidence linking breast implants to an increased cancer risk in the decade following surgery.
- Current findings are encouraging regarding the safety of breast implants concerning cancer development.
- Extended long-term follow-up is essential to comprehensively evaluate any potential late-onset adverse effects.